AbelZeta Receives FDA RMAT and Fast Track Designations for Anti-CD20/CD19 Bispecific CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma

The designations, granted under IND STN 32908, come as the company plans a Phase 2 study in patients whose lymphoma progressed after prior CAR T-cell therapy.

Key Points

  • The FDA granted RMAT and Fast Track designations to Prizlon-cel, an investigational anti-CD20/CD19 bispecific CAR-T therapy for relapsed or refractory large B-cell lymphoma.
  • AbelZeta plans a Phase 2 study in patients whose disease progressed after prior CAR T-cell therapy and a randomized second-line study.
  • The designations were granted under IND STN 32908, which the FDA cleared in August 2026.

AbelZeta Inc., a Rockville, Maryland–based clinical-stage biopharmaceutical company developing cell therapies for oncology and inflammatory and immunological diseases, announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to Prizloncabtagene Autoleucel (Prizlon-cel), also known as A-CAR039, an investigational anti-CD20/CD19 bispecific CAR-T therapy for relapsed or refractory (r/r) large B-cell lymphoma (LBCL). The designations were granted under AbelZeta’s Investigational New Drug (IND) application (STN 32908).

AbelZeta is pursuing a development strategy spanning later-line patients previously treated with FDA-approved CAR T-cell therapies and patients treated earlier in the course of disease. The company plans to evaluate Prizlon-cel in ABZT-121 (NCT07875413), a Phase 2 study in patients with r/r LBCL following treatment with an FDA-approved, commercially available CAR T-cell therapy. AbelZeta intends to evaluate whether results from ABZT-121 could support a potential accelerated-approval pathway in this population, subject to clinical results and future discussions with the FDA. In parallel, the company is developing ABZT-131, a randomized clinical study of Prizlon-cel in second-line r/r LBCL, intended to evaluate the therapy earlier in the treatment course and further define its potential role relative to established CAR T-cell therapies.

RMAT designation provides opportunities for intensive FDA interaction regarding clinical development, including discussions intended to support efficient development and potential approval. Fast Track designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical need and may provide opportunities for more frequent FDA interactions and rolling review of portions of a future Biologics License Application, if applicable requirements are met.

“These dual FDA designations are important milestones for Prizlon-cel and support our strategy to develop it across multiple treatment settings in r/r LBCL,” said Tony Liu, Chief Executive Officer of AbelZeta. “Our near-term development strategy includes patients whose disease has progressed following prior CAR T-cell therapy, a population with substantial unmet medical need, while we are also preparing to evaluate Prizlon-cel earlier in the treatment course through a randomized second-line program. We look forward to working closely with the FDA as we advance both elements of this development strategy.”

Recent Milestones

In July 2026, AbelZeta regained all global development, regulatory, manufacturing, commercialization, and other collaboration rights relating to Prizlon-cel. In August 2026, the company received FDA clearance of its IND application (STN 32908) to advance U.S. clinical development of Prizlon-cel in r/r LBCL.

AbelZeta conducts research and development in its own GMP facilities, with a pipeline comprising multiple CAR-T therapies.

Want to keep up on regenerative medicine? Get the weekly newsletter here.

Discussion

Sign in to join the discussion.

Similar stories